Market Place
Sourcing Support
Sanofi to acquire Provention Bio for $2.9 billion
14 Mar 2023 //
PRESS RELEASE
Provention Bio Announces Closing of Second Tranche with Hercules Capital
02 Feb 2023 //
PR NEWSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Almac Pharma Services Supports Launch of Provention Bio’s TZIELD
13 Dec 2022 //
CONTRACTPHARMA
JDRF and its affiliates celebrate Teplizumab approval
22 Nov 2022 //
GLOBENEWSWIRE
Amber Specialty Pharmacy Selected to Dispense TZIELD
21 Nov 2022 //
BUSINESSWIRE
First-of-its-kind Type 1 diabetes drug wins FDA approval
19 Nov 2022 //
BIOPHARMADIVE
U.S. FDA greenlights Provention Bio`s diabetes drug
18 Nov 2022 //
REUTERS
Provention`s Biologic Tzield (Teplizumab) Receives Approval in the U.S.
17 Nov 2022 //
FDA
FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes
17 Nov 2022 //
PRNEWSWIRE
Provention Bio lays commercial groundwork as FDA decision looms
06 Oct 2022 //
FIERCEPHARMA
FDA delays review of Provention Bio’s embattled diabetes drug
01 Jul 2022 //
FIERCEBIOTECH
Provention Bio Extends FDA User Fee Goal Date for Teplizumab to November 17
30 Jun 2022 //
PRNEWSWIRE
Provention Bio to Host a May 19, 2022 Virtual Investor Event for Teplizumab
12 May 2022 //
PRNEWSWIRE
FDA Accepts Provention`s BLA Resubmission for Teplizumab in Type 1 Diabetes
21 Mar 2022 //
PRNEWSWIRE
Provention Bio Announces BLA Resubmission for Teplizumab to Address CRL
22 Feb 2022 //
PRNEWSWIRE
Provention hires 3rd exec as it awaits FDA meeting for lead drug
18 Nov 2021 //
FIERCEBIOTECH
Provention Bio hires early research exec from Gossamer
09 Nov 2021 //
FIERCEBIOTECH
Provention Bio Receives CR) to Biologics License Application for Teplizumab
07 Jul 2021 //
PR NEWSWIRE
Provention Bio Receives CR) to Biologics License Application for Teplizumab
07 Jul 2021 //
PR NEWSWIRE
Provention Bio Announces U.S. FDA Filing of a BLA and Priority Review
04 Jan 2021 //
PRNEWSWIRE
10 years later, teplizumab gets a second shot at an FDA OK; J&J file
04 Jan 2021 //
ENDPTS
Provention Bio Completes Rolling Submission of the (BLA) for Teplizumab
02 Nov 2020 //
PRNEWSWIRE
Provention Bio Files Clinical Module for Teplizumab for Delay of Clinical T1D
30 Sep 2020 //
PRNEWSWIRE
Provention Bio advances U.S. marketing application for T1D med teplizumab
30 Sep 2020 //
SEEKING ALPHA
AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio
25 Aug 2020 //
PRNEWSWIRE
Provention Bio`s Teplizumab Continued to Significantly Delay the Onset of (T1D)
15 Jun 2020 //
PROVENTIONBIO
Provention Bio`s Teplizumab Continued Delay the Onset of Insulin-Dependent T1D
15 Jun 2020 //
PRNEWSWIRE
Provention Bio Initiates Rolling s BLAfor Teplizumab
16 Apr 2020 //
PRNEWSWIRE
Porton Biopharma Limited Licenses Erwinase® to Clinigen
16 Apr 2020 //
PHARMABIZ
J&J drops its option on Provention Bio drug after trial failure
04 Jan 2020 //
ENDPTS
Provention Bio`s diabetes drug gains PRIME status; Avrobio earns orphan status
26 Oct 2019 //
ENDPTS
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation
24 Oct 2019 //
PR NEWSWIRE
Jeffrey Bluestone plots late-stage comeback
11 Jun 2019 //
ENDPTS
After a 33y odyssey, Jeffrey Bluestone grabs a ringside seat drug teplizumab
28 Mar 2019 //
ENDPTS
